Dysregulated Immunity and Immunotherapy after Sepsis
暂无分享,去创建一个
L. Moldawer | P. Efron | A. Mohr | Lauren S Kelly | Dijoia B. Darden | Brittany P Fenner | Lauren S. Kelly
[1] L. Moldawer,et al. Immunological Endotyping of Chronic Critical Illness After Severe Sepsis , 2021, Frontiers in Medicine.
[2] P. Efron,et al. The Hematopoietic Stem/Progenitor Cell Response to Hemorrhage, Injury, and Sepsis: A Review of Pathophysiology , 2020, Shock.
[3] L. Moldawer,et al. Abdominal sepsis patients have a high incidence of chronic critical illness with dismal long-term outcomes. , 2020, American journal of surgery.
[4] B. Brumback,et al. Older Sepsis Survivors Suffer Persistent Disability Burden and Poor Long-Term Survival , 2020, Journal of the American Geriatrics Society.
[5] D. Gallego-Ortega,et al. Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer , 2020, Cells.
[6] M. D. de Groot,et al. Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS) after Polytrauma: A Rare Syndrome with Major Consequences , 2020, Journal of clinical medicine.
[7] L. Moldawer,et al. Persistently increased cell-free DNA concentrations only modestly contribute to outcome and host response in sepsis survivors with chronic critical illness. , 2019, Surgery.
[8] Marie-Pierre L. Gauthier,et al. Myeloid-derived suppressor cell function and epigenetic expression evolves over time after surgical sepsis , 2019, Critical Care.
[9] P. Pickkers,et al. Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series , 2019, BMC Infectious Diseases.
[10] S. Anton,et al. Current Epidemiology of Surgical Sepsis: Discordance Between Inpatient Mortality and 1-Year Outcomes. , 2019, Annals of surgery.
[11] T. Foster,et al. Age and Sex Influence the Hippocampal Response and Recovery Following Sepsis , 2019, Molecular Neurobiology.
[12] L. Moldawer,et al. Persistently Elevated Glucagon-Like Peptide-1 Levels among Critically Ill Surgical Patients after Sepsis and Development of Chronic Critical Illness and Dismal Long-Term Outcomes. , 2019, Journal of the American College of Surgeons.
[13] B. Brumback,et al. The Development of Chronic Critical Illness Determines Physical Function, Quality of Life, and Long-Term Survival Among Early Survivors of Sepsis in Surgical ICUs* , 2019, Critical care medicine.
[14] T. Roger,et al. Myeloid-Derived Suppressor Cells in Sepsis , 2019, Front. Immunol..
[15] K. Tenbrock,et al. Reactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression , 2018, Front. Immunol..
[16] L. Moldawer,et al. Chronic Critical Illness and the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome , 2018, Front. Immunol..
[17] H. Ueno,et al. Innate Immunity in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and Its Implications for Therapy , 2018, Front. Immunol..
[18] R. Hotchkiss,et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. , 2018, JCI insight.
[19] V. Badovinac,et al. Sepsis-Induced T Cell Immunoparalysis: The Ins and Outs of Impaired T Cell Immunity , 2018, The Journal of Immunology.
[20] D. Gabrilovich,et al. Myeloid-derived suppressor cells coming of age , 2018, Nature Immunology.
[21] R. Bernabei,et al. Circulating Mitochondrial DNA at the Crossroads of Mitochondrial Dysfunction and Inflammation During Aging and Muscle Wasting Disorders. , 2018, Rejuvenation research.
[22] B. Brumback,et al. Benchmarking clinical outcomes and the immunocatabolic phenotype of chronic critical illness after sepsis in surgical intensive care unit patients , 2017, The journal of trauma and acute care surgery.
[23] Susan Gruber,et al. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014 , 2017, JAMA.
[24] M. Fleshner,et al. Exosomes, DAMPs and miRNA: Features of Stress Physiology and Immune Homeostasis. , 2017, Trends in immunology.
[25] B. Brumback,et al. Evidence for Persistent Immune Suppression in Patients Who Develop Chronic Critical Illness After Sepsis , 2017, Shock.
[26] G. Salekdeh,et al. Advanced glycation end‐products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases , 2017, Pharmacology & therapeutics.
[27] Xiuwen Wu,et al. Elevated Levels of Plasma Mitochondrial DNA Are Associated with Clinical Outcome in Intra-Abdominal Infections Caused by Severe Trauma. , 2017, Surgical infections.
[28] B. Brumback,et al. Human Myeloid-derived Suppressor Cells are Associated With Chronic Immune Suppression After Severe Sepsis/Septic Shock , 2017, Annals of surgery.
[29] L. Moldawer,et al. Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome , 2017, Critical care medicine.
[30] R. Hotchkiss,et al. Frontline Science: Defects in immune function in patients with sepsis are associated with PD‐1 or PD‐L1 expression and can be restored by antibodies targeting PD‐1 or PD‐L1 , 2016, Journal of leukocyte biology.
[31] R. Hotchkiss,et al. Comparison of monocyte human leukocyte antigen-DR expression and stimulated tumor necrosis factor alpha production as outcome predictors in severe sepsis: a prospective observational study , 2016, Critical Care.
[32] S. Brakenridge,et al. The long-term burden of severe sepsis and septic shock: Sepsis recidivism and organ dysfunction , 2016, The journal of trauma and acute care surgery.
[33] E. Sherwood,et al. Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression. , 2016, Pharmacological research.
[34] Peter J. Murray,et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.
[35] R. Bellomo,et al. Timing of onset and burden of persistent critical illness in Australia and New Zealand: a retrospective, population-based, observational study. , 2016, The Lancet. Respiratory medicine.
[36] R. Hotchkiss,et al. Sepsis and septic shock , 2016, Nature Reviews Disease Primers.
[37] P. Pickkers,et al. Plasma Nuclear and Mitochondrial DNA Levels, and Markers of Inflammation, Shock, and Organ Damage in Patients with Septic Shock , 2016, Shock.
[38] M. Shankar-Hari,et al. Evidence for a causal link between sepsis and long-term mortality: a systematic review of epidemiologic studies , 2016, Critical Care.
[39] W. Gause,et al. Innate cell communication kick-starts pathogen-specific immunity , 2016, Nature Immunology.
[40] M. Delano,et al. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? , 2016, The Journal of clinical investigation.
[41] J. Lord,et al. Immunesenescence and inflammaging: A contributory factor in the poor outcome of the geriatric trauma patient , 2015, Ageing Research Reviews.
[42] Sun-Mee Lee,et al. DAMPs activating innate immune responses in sepsis , 2015, Ageing Research Reviews.
[43] J. Minei,et al. Mitochondrial ROS Induces Cardiac Inflammation via a Pathway through mtDNA Damage in a Pneumonia-Related Sepsis Model , 2015, PloS one.
[44] Xue Han,et al. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.
[45] H. Baker,et al. A Detailed Characterization of the Dysfunctional Immunity and Abnormal Myelopoiesis Induced by Severe Shock and Trauma in the Aged , 2015, The Journal of Immunology.
[46] F. Moore,et al. Persistent inflammatory, immunosuppressed, catabolic syndrome (PICS): A new phenotype of multiple organ failure. , 2015, Journal of advanced nutritional and human metabolism.
[47] A. Friggeri,et al. STAT5 phosphorylation in T cell subsets from septic patients in response to recombinant human interleukin‐7: a pilot study , 2015, Journal of leukocyte biology.
[48] G. Van den Berghe,et al. Soluble RAGE and the RAGE Ligands HMGB1 and S100A12 in Critical Illness: Impact of Glycemic Control with Insulin and Relation with Clinical Outcome , 2015, Shock.
[49] W. Chao,et al. Importance of Toll-like Receptor 2 in Mitochondrial Dysfunction during Polymicrobial Sepsis , 2014, Anesthesiology.
[50] L. Rydén,et al. A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram‐positive cases , 2014, Journal of leukocyte biology.
[51] S. Lemeshow,et al. Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study , 2014, Intensive Care Medicine.
[52] B. Giraudeau,et al. Circulating Immature Granulocytes With T-Cell Killing Functions Predict Sepsis Deterioration* , 2014, Critical care medicine.
[53] N. Anstey,et al. Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients , 2014, Critical Care.
[54] R. Hotchkiss,et al. Parallels between cancer and infectious disease. , 2014, New England Journal of Medicine.
[55] R. Hotchkiss,et al. Reactivation of Multiple Viruses in Patients with Sepsis , 2014, PloS one.
[56] M. Heneka,et al. Long-term cerebral consequences of sepsis , 2014, The Lancet Neurology.
[57] A. Gabrielli,et al. Computer versus paper system for recognition and management of sepsis in surgical intensive care , 2014, The journal of trauma and acute care surgery.
[58] R. Hotchkiss,et al. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy , 2013, Nature Reviews Immunology.
[59] Chibeza C. Agley,et al. Acute skeletal muscle wasting in critical illness. , 2013, JAMA.
[60] M. Boermeester,et al. S100A12 and Soluble Receptor for Advanced Glycation End Products Levels During Human Severe Sepsis , 2013, Shock.
[61] R. Hotchkiss,et al. Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis , 2013, Critical Care.
[62] R. Tompkins,et al. Development of a Genomic Metric That Can Be Rapidly Used to Predict Clinical Outcome in Severely Injured Trauma Patients* , 2013, Critical care medicine.
[63] S. Singhal,et al. Myeloid derived suppressor cells , 2013, Oncoimmunology.
[64] M. Fleshner,et al. The inflammasome and danger associated molecular patterns (DAMPs) are implicated in cytokine and chemokine responses following stressor exposure , 2013, Brain, Behavior, and Immunity.
[65] M. Fleshner. Stress-evoked sterile inflammation, danger associated molecular patterns (DAMPs), microbial associated molecular patterns (MAMPs) and the inflammasome , 2013, Brain, Behavior, and Immunity.
[66] C. Malcus,et al. Decreased T-Cell Repertoire Diversity in Sepsis: A Preliminary Study* , 2013, Critical care medicine.
[67] J. Marko,et al. ATP Hydrolysis Enhances RNA Recognition and Antiviral Signal Transduction by the Innate Immune Sensor, Laboratory of Genetics and Physiology 2 (LGP2)* , 2012, The Journal of Biological Chemistry.
[68] C. Malcus,et al. IL-7 Restores Lymphocyte Functions in Septic Patients , 2012, The Journal of Immunology.
[69] R. Hotchkiss,et al. Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. , 2012, The Journal of infectious diseases.
[70] Janet S. Lee,et al. STAT1-Regulated Lung MDSC-like Cells Produce IL-10 and Efferocytose Apoptotic Neutrophils With Relevance In Resolution of Bacterial Pneumonia , 2012, Mucosal Immunology.
[71] R. Hotchkiss,et al. A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis , 2012, Critical Care.
[72] L. Moldawer,et al. Persistent inflammation and immunosuppression: A common syndrome and new horizon for surgical intensive care , 2012, The journal of trauma and acute care surgery.
[73] H. Wunsch,et al. Population Burden of Long‐Term Survivorship After Severe Sepsis in Older Americans , 2012, Journal of The American Geriatrics Society.
[74] M. Lederman,et al. Effects of Recombinant Human Interleukin 7 on T-Cell Recovery and Thymic Output in HIV-Infected Patients Receiving Antiretroviral Therapy: Results of a Phase I/IIa Randomized, Placebo-Controlled, Multicenter Study , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[75] Xin Lin,et al. C-type lectin receptor-induced NF-κB activation in innate immune and inflammatory responses , 2012, Cellular and Molecular Immunology.
[76] R. Hotchkiss,et al. Immunosuppression in patients who die of sepsis and multiple organ failure. , 2011, JAMA.
[77] John D. Storey,et al. A genomic storm in critically injured humans , 2011, The Journal of experimental medicine.
[78] B. McKinley,et al. Computer protocol facilitates evidence-based care of sepsis in the surgical intensive care unit. , 2011, The Journal of trauma.
[79] T. Fry,et al. Harnessing the biology of IL-7 for therapeutic application , 2011, Nature Reviews Immunology.
[80] B. Allaouchiche,et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients , 2011, Critical care.
[81] Lyle L. Moldawer,et al. A Paradoxical Role for Myeloid-Derived Suppressor Cells in Sepsis and Trauma , 2011, Molecular medicine.
[82] L. Kao,et al. The epidemiology of sepsis in general surgery patients. , 2011, The Journal of trauma.
[83] Yan Zhang,et al. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients , 2011, Critical care.
[84] Fei Wang,et al. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis , 2011, Critical care.
[85] M. Saleh,et al. The Inflammasomes: Molecular Effectors of Host Resistance Against Bacterial, Viral, Parasitic, and Fungal Infections , 2010, Front. Microbio..
[86] Yan Zhang,et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction , 2010, Critical care.
[87] Je-in Youn,et al. The biology of myeloid‐derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity , 2010, European journal of immunology.
[88] Greg Noel,et al. A Ribonucleotide Reductase Inhibitor Reverses Burn-Induced Inflammatory Defects , 2010, Shock.
[89] Shannon S Carson,et al. One-Year Trajectories of Care and Resource Utilization for Recipients of Prolonged Mechanical Ventilation , 2010, Annals of Internal Medicine.
[90] R. Hotchkiss,et al. Delayed administration of anti‐PD‐1 antibody reverses immune dysfunction and improves survival during sepsis , 2010, Journal of leukocyte biology.
[91] N. Voirin,et al. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock , 2010, Intensive Care Medicine.
[92] J. Magarian Blander,et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function , 2010, The Journal of experimental medicine.
[93] S. Akira,et al. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.
[94] P. Pronovost,et al. Long-term mortality and quality of life in sepsis: A systematic review* , 2010, Critical care medicine.
[95] W. McGee,et al. Expectations and outcomes of prolonged mechanical ventilation. , 2010, Critical care medicine.
[96] R. Hotchkiss,et al. IL-7 Promotes T Cell Viability, Trafficking, and Functionality and Improves Survival in Sepsis , 2010, The Journal of Immunology.
[97] A. Coyle,et al. HMGB1 and RAGE in inflammation and cancer. , 2010, Annual review of immunology.
[98] Kaoru Tominaga,et al. Activation of innate immune antiviral response by NOD2 , 2009, Nature Immunology.
[99] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.
[100] D. Venzon,et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets , 2008, The Journal of experimental medicine.
[101] Graham R. Foster,et al. Interferons at age 50: past, current and future impact on biomedicine , 2007, Nature Reviews Drug Discovery.
[102] E. Wherry,et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.
[103] L. Moldawer,et al. MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis , 2007, The Journal of experimental medicine.
[104] L. Moldawer,et al. Increased Natural CD4+CD25+ Regulatory T Cells and Their Suppressor Activity Do Not Contribute to Mortality in Murine Polymicrobial Sepsis1 , 2006, The Journal of Immunology.
[105] Philip J. R. Goulder,et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.
[106] S. Rosenberg,et al. IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory Cells , 2006, Journal of immunotherapy.
[107] G. Freeman,et al. Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.
[108] L. Moldawer,et al. The origins of cachexia in acute and chronic inflammatory diseases. , 2006, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.
[109] M. Belosevic,et al. Regulation of myeloid development and function by colony stimulating factors. , 2004, Developmental and comparative immunology.
[110] T. Okazaki,et al. PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver , 2003, The Journal of experimental medicine.
[111] J. Vincent,et al. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis* , 2003, Critical care medicine.
[112] R. Flavell,et al. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.
[113] S. Akira,et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5 , 2001, Nature.
[114] S. Akira,et al. A Toll-like receptor recognizes bacterial DNA , 2000, Nature.
[115] S. Belknap,et al. A Randomized Controlled Trial of Filgrastim as an Adjunct to Antibiotics for Treatment of Hospitalized Patients with Community-Acquired Pneumonia , 1998 .
[116] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[117] K. Asadullah,et al. Monocyte deactivation in septic patients: Restoration by IFN-γ treatment , 1997, Nature Medicine.
[118] K. Asadullah,et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. , 1997, Archives of internal medicine.
[119] I. Chaudry,et al. IMMUNE DYSFUNCTION IN MURINE POLYMICROBIAL SEPSIS: MEDIATORS, MACROPHAGES, LYMPHOCYTES AND APOPTOSIS , 1996, Shock.
[120] S. Streat,et al. Sequential changes in the metabolic response in critically injured patients during the first 25 days after blunt trauma. , 1996, Annals of surgery.
[121] F. Lewis,et al. Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial. , 1994, Archives of surgery.
[122] J. Cavaillon,et al. Dysregulation of in vitro cytokine production by monocytes during sepsis. , 1991, The Journal of clinical investigation.
[123] L. Moldawer,et al. Dysregulated myelopoiesis and hematopoietic function following acute physiologic insult , 2018, Current opinion in hematology.
[124] S. Brakenridge,et al. Chronic Critical Illness: Application of What We Know. , 2018, Nutrition in clinical practice.
[125] S. Vieira,et al. Chronic critical illness: are we saving patients or creating victims? , 2017, Revista Brasileira de terapia intensiva.
[126] T. Waldmann,et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] Jacques Duranteau,et al. Oxidative stress and endothelial dysfunction during sepsis. , 2011, Frontiers in bioscience.
[128] M. Singer. Metabolic failure. , 2005, Critical care medicine.
[129] Joseph T. Murphy,et al. Reactive oxygen species mediate endotoxin-induced human dermal endothelial NF-kappaB activation. , 2003, The Journal of surgical research.
[130] C. Janeway,et al. Innate immune recognition. , 2002, Annual review of immunology.
[131] S. Belknap,et al. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group. , 1998, The Journal of infectious diseases.
[132] K. Asadullah,et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. , 1997, Nature medicine.